Global Peptides Market Overview
Peptides Market Size Was Valued at USD 43.12 Billion In 2024. The Global Peptides Industry is Projected to Grow from USD 45.58 Billion In 2025 To USD 97.18 Billion By 2035, Exhibiting A Compound Annual Growth Rate (CAGR) Of 7.11% During the Forecast Period (2025 - 2035).
Growing Awareness of Peptide-Based Therapeutics and Growing Acquisition and Agreement Associated With The Peptide Products And Increasing Launch of Platform To Accelerate Peptide Drug Discovery Research is driving the Peptides Market.
As per Analyst at MRFR,” The growing awareness of peptide-based therapeutics is significantly boosting the global market for peptide drugs, as more healthcare professionals and patients recognize their potential in treating a variety of conditions, including cancer, diabetes, and autoimmune disorders. As peptides are increasingly understood for their specificity and reduced side effects compared to traditional small molecule drugs, demand for these innovative therapies is surging”
Source: Secondary Research, Primary Research, MRFR Database, and Analyst Review
Peptides Market Trends
INCREASING FUNDING ASSOCIATED WITH PEPTIDE PLATFORM AND DRUG.
Increasing funding and investment in the global peptide market is poised to unlock significant lucrative opportunities by accelerating research and development, enhancing production capabilities, and expanding market reach. With more financial resources, companies can innovate in peptide synthesis and formulation, leading to the development of novel therapeutic applications in areas such as oncology, diabetes, and autoimmune diseases. This influx of capital can also facilitate partnerships and collaborations, driving advancements in technology and improving manufacturing processes for greater efficiency and scalability. For instance,
March 2024: Department of Urology at The University of Kansas Cancer Center has received a nearly USD 1.4 billion grant from the U.S. Department of Defense (DoD) to develop a short peptide-based therapy for prostate cancer. As prostate cancer progresses, it often develops resistance to standard treatments like androgen-deprivation therapy and androgen receptor antagonists. This resistance presents significant challenges in effective treatment. However, recent research indicates a potential breakthrough by targeting the stability of the androgen receptor protein, a critical factor in the cancer's development and progression. The grant will support further exploration of this innovative therapeutic approach.
July 2024: CordenPharma (US) had made a substantial investment of nearly one billion dollars in peptide plants across the US and Europe, driven by the surging popularity of peptide-based weight-loss and antidiabetes drugs. The strong demand for glucagon-like peptide 1 (GLP-1) agonists is a primary catalyst for CordenPharma to expand its peptide services. Additionally, the growing need for peptides in areas such as oncology and radiopharmaceuticals further underscore this investment. With part of the new funding, CordenPharma plans to add reactors for peptide synthesis at its Boulder, Colorado facility, enhancing its production capabilities. The company is also set to establish a new facility in Europe dedicated to early-to-late-stage commercial manufacturing, positioning itself to meet the increasing global demand for peptide therapies.
Peptides Market Segment Insights
Global Peptides Route of Administration Insights
Based on Route of Administration, the Peptides Market has been bifurcated into Oral and Parenteral. Parenteral is further segmented into Intravenous, Subcutaneous, and Intramuscular. The parenteral segment held the largest market share in 2024, and the oral segment is the fastest-growing segment during the forecast period (2024 -2035).
The oral route has gained traction due to its non-invasive nature, making it more convenient for patients, particularly for chronic diseases requiring long-term therapy. According to the Centre for Diseases Control and Prevention in 2019, the prevalence of chronic diseases in adults was around 60% globally, and it is reportedly much higher among elderly people. It is estimated that about 70% of adults will die of one or more chronic diseases. The rising prevalence of cancer, cardiovascular disorders, diabetes, Parkinson's disease, and other conditions demands oral medications.
However, challenges such as the low bioavailability of peptides via the oral route have driven significant research into advanced formulations to improve peptide absorption. Government agencies, particularly in the US and Europe, have supported initiatives that encourage innovation in oral peptide formulations, aiming to enhance patient compliance and reduce healthcare costs. The rising focus on patient-friendly drug delivery systems and growing interest in self-administrable therapies are key drivers in this segment.
On the other hand, the parenteral route dominates the peptides market due to its higher efficacy and bioavailability. Intravenous administration is more favored for critical care treatments such as cardiovascular diseases and others requiring quick onset action. Government healthcare expenditure for critical care treatments in developed markets such as the US, Japan, and Europe for a disease like cancer has helped increase the adoption rate of IV peptide treatments. Subcutaneous administration is highly used for chronic conditions such as diabetes and obesity with various long-acting peptide formulations that have obtained market approval. For instance, in In June 2021, semaglutide (2.4 mg, Wegovy) received USFDA approval as a treatment for obesity or overweight in adults. Apart from this, the rise in chronic diseases, improvement in healthcare infrastructure in emerging markets like China and India, is thus supporting growth in the Subcutaneous segment. Besides, Intramuscular peptide administration is showing steady growth, more so in hormonal treatments such as human growth hormone deficiency and hypoparathyroidism where sustained-release formulations are developed.
Global Peptides Age Group Insights
Based on Age Group, the Peptides Market has been bifurcated into Pediatrics and Adult. The adult segment held the largest market in 2024, and the pediatric segment is the fastest growing segment during the forecast period.
In the Pediatrics segment, the incidence of pediatric diseases has been on the rise with diseases such as diabetes, growth hormone deficiencies, and rare genetic disorders. Ensuring better outcomes for the future generation around the globe has become a goal and priority among governments and healthcare organizations when it comes to advanced treatments like peptide therapy. Pediatric preparations of peptide drugs are designed to be sensitive to the diverse metabolic and physiological needs of children and thereby increase the scope for clinical trials and investments in R&D. The incidence of pediatric diabetes is on the rise not only in developing nations but also in well-developed nations like the US and Europe, due to which there is an increased effort in developing child-friendly peptide-based treatments for glycemic control. According to global health statistics, the incidence of pediatric endocrine disorders has been gradually increasing over the last decade. This further increases the demand for innovative therapies.
The dominant chronic diseases like cardiovascular diseases and metabolic disorders with a growing prevalence have constituted an important growth driver in the Adult segment of peptide-based treatments. Peptide therapies are also increasingly trending in adults. This can be seen in the management of age-related conditions such as neurodegenerative diseases. Moreover, the sales of peptides for anti-obesity and anti-diabetic treatments will grow with the increasing rates of obesity and diabetes in developed and developing countries. In this regard, the public, government, and health administrations have made investments in the development of medical products and been placing peptide medicine on the commercial map. Indeed, in 2020, FDA and EMA approvals for peptide drugs treating adults showed significant surge.
Figure 1: Peptides Market, By Age Group, 2024 & 2035 (USD Billion)
Global Peptides Indication Insights
Based on Indication, the Peptides Market has been segmented into Diabetes Mellitus, Obesity, Short Bowel Syndrome (SBS), Human Growth Hormone (hGH) Deficiency, Hemophilia, Acromegaly, Hypoparathyroidism, Cancer, Neurological disorders, Cardiovascular Disorders, and Others. Human Growth Hormone (hGH) Deficiency is further bifurcated into Pediatrics and Adult. The diabetes mellitus segment held the largest market in 2024, and the human growth hormone (HGH) segment is the fastest growing segment during the forecast period.
Diabetes Mellitus is one of the primary drivers for the peptide market due to the rising global incidence of diabetes. According to the International Diabetes Federation (IDF), in 2021, approximately 537 billion people worldwide were living with diabetes, and this number is expected to soar to 643 billion by 2030. Similarly, according to the American Diabetes Association, diabetes affected 38.4 billion Americans, or 11.6% of the population, in 2021. Type 1 diabetes affects around 2.0 billion Americans, including approximately 304,000 children and adolescents. The growing adoption of peptide-based therapies, particularly GLP-1 receptor agonists such as Liraglutide and Semaglutide, is playing a critical role in improving glycemic control and reducing the risk of cardiovascular complications in diabetic patients. Governments in regions like the US, Europe, and Asia-Pacific are increasing healthcare expenditure to manage the diabetes burden, thereby promoting the use of innovative peptide therapies.
Similarly, the growing prevalence of obesity is another key factor driving the demand for peptides. According to the WHO, in 2022, one in eight individuals globally was living with obesity. Peptide-based treatments like GLP-1 analogs are gaining popularity as they aid in appetite suppression and weight loss. The increased government focus on tackling obesity-related diseases, combined with rising public health initiatives, is boosting the growth of this segment.
In the case of Short Bowel Syndrome (SBS), the increasing number of cases, especially in pediatric populations, is driving demand for peptide-based therapies that improve nutrient absorption. Teduglutide, a peptide therapy approved by the FDA, has become a major therapeutic option for SBS patients, addressing the malabsorption issues inherent to the condition. This, along with government support for orphan drugs and rare disease treatments, is expected to accelerate the adoption of peptide therapies for SBS.
Global Peptides Distribution Channel Insights
Based on Distribution Channel, the Peptides Market has been segmented into Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies. The hospital pharmacies segment held the largest market in 2024, and the online pharmacies segment is the fastest growing segment during the forecast period.
Due to increased prescription of peptide-based drugs in critical and complex conditions such as diabetes, and cardiovascular diseases among others, drug therapy in hospitals forms a vast market. Hospitals are centers that have the sole responsibility of carrying out peptide therapy, especially for critical care and specialized treatments. The world is witnessing an increase in hospital admissions with chronic diseases. With the availability of advanced peptide drugs on the hospitals, this segment is experiencing a boost in demand. The hospitals are not only working on the infrastructure of hospitals but are also upgrading the therapeutics available to patients, which include access to peptides, further fueling the market.
Retail Pharmacies are also seeing a steady hike in the demand for peptide drugs. With more peptide-based drugs receiving approval for outpatient use, the treated patients can directly buy these drugs from retail pharmacies. Increasingly diagnosed lifestyle diseases like obesity and diabetes in the body have increased the demand for peptide therapies, many of which are now available in retail pharmacies. The convenience of accessing peptide-based drugs through a retail outlet, along with an enhancement of the pharmaceutical chain, is also a key growth driver for this segment. Public health initiatives and insurance coverage for drugs taken for chronic diseases have cemented the retail pharmacies in the marketplace of peptides.
Online pharmacies are fast growing as well in this era of e-health. Online patients, desiring accessibility and convenience, especially while taking chronic diseases, are opting for buying peptide drugs on online platforms. Telemedicine, digital health platforms, and online prescription services have made the process of acquiring peptide medications much easier through personal homes. Governments in regions such as North America and Europe encourage the digitization of healthcare services, which boosts the consumption of online pharmacies. Acceptance of online pharmacies, competitive pricing, and home delivery options are factors driving this segment's growth
Global Peptides Regional Insights
Based on region, the Global Peptide Market has been segmented into North America, Europe, Asia-Pacific, and Rest of the World. North America accounted for the largest market share in 2024 and is anticipated to reach USD 31.58 billion by 2035. However, Asia-Pacific is projected to grow at the highest CAGR of 8.42% during the forecast period.
The North America Peptide Market accounted for largest market share during the forecast period. North America is further segmented into the US, & Canada. The peptides market in North America is thriving, characterized by a dynamic interplay of innovation and demand. This growth is primarily fueled by the increasing prevalence of chronic diseases, such as cancer, diabetes, and cardiovascular disorders, which drives the need for effective peptide-based therapeutics. According to the US Department of Health and Human Services, around 129 billion people in the US have at least one significant chronic disease (for example, heart disease, cancer, diabetes, obesity, or hypertension). Five of the top ten main causes of death in the United States are either preventable or closely connected with chronic conditions that can be treated. Over the last two decades, prevalence has steadily climbed, and this pattern is projected to continue. An increasing proportion of Americans suffer from several chronic illnesses; 42% have two or more, and 12% have at least five. Aside from the personal effects, chronic sickness has a significant influence on the US healthcare system. Approximately 90% of the $4.1 trillion spent on health care each year goes toward managing and treating mental health issues and chronic illnesses. On the other hand, according to Statistique Canada, in 2021, 45.1% of Canadians had at least one serious chronic illness. In 2021, around 2.5 billion Canadians reported having unmet medical needs.
The Asia-Pacific Peptide is projected to grow at a CAGR of 8.42%during the forecast period. Asia-Pacific is further segmented into the China, India, Japan, South Korea, Australia, and Rest of Asia-pacific.
The peptide market in the Asia-Pacific region is undergoing remarkable growth, fueled by a multifaceted array of drivers that are shaping its landscape. One of the most significant factors is the rising incidence of chronic diseases, including diabetes, cancer, and cardiovascular conditions. For instance, According to National Institute of Health, over 60% of diabetics living in Asia, with China and India accounting for nearly half of the total. More than 138.2 billion people in the Western Pacific, the most populated region in the globe, have diabetes, and by 2035, that figure might reach 201.8 billion. As these health challenges become more prevalent, the demand for effective peptide-based therapeutics is surging, prompting healthcare providers to seek innovative treatment options.
Figure 2: Peptides Market, by region, 2024 & 2035 (USD Billion)
Further, the major countries studied in the market report are the U.S., Canada, Mexico, Germany, France, Italy, UK, Spain, Japan, UAE, South Africa, Saudi Arabia, Argentina, and Brazil.
Global Peptides Key Market Players & Competitive Insight
Many global, regional, and local vendors characterize the Peptides Market. The market is highly competitive, with all the players competing to gain market share. Intense competition, rapid advances in technology, frequent changes in government policies, and environmental regulations are key factors that confront market growth. The vendors compete based on cost, product quality, reliability, and government regulations. Vendors must provide cost-efficient, high-quality products to survive and succeed in an intensely competitive market.
The major players in the market include AMGEN INC., ELI LILLY AND COMPANY, PFIZER INC., SUN PHARMACEUTICAL INDUSTRIES LTD., MERCK KGAA, TAKEDA PHARMACEUTICAL COMPANY LIMITED, ASTRAZENECA, NOVARTIS AG, SANOFI, IRONWOOD PHARMACEUTICALS, INC., among others. The Peptides Market is a consolidated market due to increasing competition, acquisitions, mergers and other strategic market developments and decisions to improve operational effectiveness.
Key Companies in the Peptides Market include.
- AMGEN INC.
- ELI LILLY AND COMPANY
- PFIZER INC.
- SUN PHARMACEUTICAL INDUSTRIES LTD.
- MERCK KGAA
- TAKEDA PHARMACEUTICAL COMPANY LIMITED
- ASTRAZENECA
- NOVARTIS AG
- SANOFI
- IRONWOOD PHARMACEUTICALS, INC.
Global Peptides Industry Developments
- In August 2024, Eli Lilly and Company has announced that Zepbound (tirzepatide) is now available for self-pay patients with an on-label prescription, greatly increasing the supply in response to high demand. The single-dose vials are offered at a discount of 50% or more compared to the list prices of other GLP-1 medications for obesity. The single-dose vials are priced at a discount of 50% or more compared to the list prices of all other GLP-1 medications for obesity.
- In January 2024, Takeda and Protagonist Therapeutics, Inc. have signed a global license and collaboration agreement for the development and commercialization of rusfertide, an investigational injectable hepcidin mimetic peptide of the natural hormone hepcidin that was in a pivotal Phase 3 trial, VERIFY, for the treatment of Polycythemia Vera (PV).
Peptides Market Segmentation
Peptides Market By Route Of Administration Outlook (USD Billion, 2019-2035)
- Oral
- Parenteral
- Intravenous
- Subcutaneous
- Intramuscular
- Others
Peptides Market By Age Group Outlook (USD Billion, 2019-2035)
Peptides Market By Indication Outlook (USD Billion, 2019-2035)
- Diabetes Mellitus
- Obesity
- Short Bowel Syndrome (SBS)
- Human Growth Hormone (HGH) Deficiency
- Hemophilia
- Acromegaly
- Hypoparathyroidism
- Cancer
- Neurological disorders
- Cardiovascular Disorders
- Others
Peptides Market By Distribution Channel Outlook (USD Billion, 2019-2035)
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
Global Peptides Regional Outlook
- North America
- Europe
- Germany
- France
- UK
- Spain
- Italy
- Rest of Europe
- Asia-Pacific
- China
- Japan
- India
- South Korea
- Rest of Asia-Pacific
- Middle East and Africa
- Latin America
| Report Attribute/Metric |
Details |
| Market Size 2024 |
USD 43.12 Billion |
| Market Size 2025 |
USD 45.58 Billion |
| Market Size 2035 |
USD 97.18 Billion |
| Compound Annual Growth Rate (CAGR) |
7.11% (2025-2035) |
| Base Year |
2024 |
| Market Forecast Period |
2025-2035 |
| Historical Data |
2019- 2024 |
| Market Forecast Units |
Value (USD Billion) |
| Report Coverage |
Revenue Forecast, Market Competitive Landscape, Growth Factors, and Trends |
| Segments Covered |
By Route Of Administration, By Age Group, By Indication, By Distribution Channel and Region. |
| Geographies Covered |
North America, Europe, Asia-Pacific, Middle East & Africa, and Latin America. |
| Countries Covered |
The U.S., Canada, Mexico, Germany, France, Italy, UK, Spain, China, Japan, India, UAE, South Africa, Saudi Arabia, Argentina, and Brazil. |
| Key Companies Profiled |
AMGEN INC., ELI LILLY AND COMPANY, PFIZER INC., SUN PHARMACEUTICAL INDUSTRIES LTD., MERCK KGAA, TAKEDA PHARMACEUTICAL COMPANY LIMITED, ASTRAZENECA, NOVARTIS AG, SANOFI, IRONWOOD PHARMACEUTICALS, INC., among others. |
| Key Market Opportunities |
·        INCREASING FUNDING ASSOCIATED WITH PEPTIDE PLATFORM AND DRUG ·        INCORPORATION OF ARTIFICIAL INTELLIGENCE IN MANUFACTURING PEPTIDE-BASED THERAPEUTICS |
| Key Market Dynamics |
·        GROWING AWARENESS OF PEPTIDE-BASED THERAPEUTICS ·        GROWING ACQUISITION AND AGREEMENT ASSOCIATED WITH THE PEPTIDE PRODUCTS |
Frequently Asked Questions (FAQ) :
The Peptides Market size is expected to be valued at USD 97.18 Billion in 2035.
The global market is projected to grow at a CAGR of 7.11% during the forecast period, 2024-2035.
North America had the largest share of the global market.
The key players in the market are Astec Industries AMGEN INC., ELI LILLY AND COMPANY, PFIZER INC., SUN PHARMACEUTICAL INDUSTRIES LTD., MERCK KGAA, TAKEDA PHARMACEUTICAL COMPANY LIMITED, ASTRAZENECA, NOVARTIS AG, SANOFI, IRONWOOD PHARMACEUTICALS, INC., among others.
The Diabetes Mellitus category dominated the market in 2024.
Parenteral segment had the largest revenue share of the global market.
